Multiple tumor nodules are seen with increasing frequency in clinical practice. On the basis of the 2015 WHO classification of lung tumors, we assessed the reproducibility of the comprehensive histologic assessment to distinguish second primary lung cancers (SPLCs) from intrapulmonary metastases (IPMs), looking for the most distinctive histologic features. An international panel of lung pathologists reviewed a scanned sequential cohort of 126 tumors from 48 patients and recorded an agreed set of histologic features, including tumor typing and predominant pattern of adenocarcinoma, thereby opining whether the case was SPLC, IPM, or a combination thereof. Cohen k statistics of 0.60 on overall assessment of SPLC or IPM indicated a good agreement. Likewise, there was good agreement (k score 0.64, p < 0.0001) between WHO histologic pattern in individual cases and SPLC or IPM status, but the proportions diversified for histologic pattern and SPLC or IPM status (McNemar test, p < 0.0001). The strongest associations for distinguishing between SPLC and IPM were observed for nuclear pleomorphism, cell size, acinus formation, nucleolar size, mitotic rate, nuclear inclusions, intraalveolar clusters, and necrosis. Conversely, the associations for lymphocytosis, mucin content, lepidic growth, vascular invasion, macrophage response, clear cell change, acute inflammation keratinization, and emperipolesis did not reach significance with tumor extent. Comprehensive histologic assessment is recommended for distinguishing SPLC from IPM with good reproducibility among lung pathologists. In addition to main histologic type and predominant patterns of histologic subtypes, nuclear pleomorphism, cell size, acinus formation, nucleolar size, and mitotic rate strongly correlate with pathologic staging status.
Introduction
Multiple tumor nodules may result from the formation of separate primary lung cancers (SPLCs) or intrapulmonary metastases (IPMs) (also termed clinically as separate tumor nodules). From 1975 until recently, distinctions between these two types of nodules were defined by the criteria of Martini and Melamed. According to these criteria, SPLCs were defined as tumors occurring in different lobes, featuring different major histologic types, or being separated by a time interval of more than 2 years. 1 Recently however, these criteria have been supplanted by comprehensive histologic assessment (CHA). 2 CHA involves determination of major histologic type, assessment of predominant and minor histologic patterns according to histologic subtyping, and evaluation of cytologic features. CHA has been shown to significantly improve the pathologic distinction between SPLC and IPM to a level comparable to that by molecular analysis. 2 Pathologic staging of lung cancer remains integral to patient management. The recently revised eighth editions of the American Joint Committee on Cancer and Union for International Cancer Control staging manuals 3, 4 include updates in the T, N and M components for both NSCC and SCLC. [5] [6] [7] These updates reflect increased interest in staging of patients with multiple tumor nodules [8] [9] [10] [11] because of the increased frequency of presentation 8 and advances in classification of tumor subtypes. 11, 12 Although TNM categories for multiple tumor nodules remain the same in the eighth edition as in the seventh, categories have been affected by changes in the histologic classification of lung cancer, 12 in particular, adenocarcinomas. 13 SPLCs continue to be staged individually, with the recommendation that multiple lesions, including ground glass lesions, be grouped with the number of lesions in brackets (e.g., [2] or [m] for multiple). Patients with IPM are staged as T3 (same lobe), T4 (different lobe in ipsilateral lung), and M1a (contralateral lung). IPMs also include those presenting with multiple areas of pneumonic consolidation that frequently correspond to invasive mucinous adenocarcinomas. 7, 13 This distinction is key to patient management because classification as SPLCs may determine that the patient be treated with surgical therapy instead of with other therapeutic approaches such as chemotherapy and radiotherapy.
The ability of pathologists to apply this approach in a reproducible fashion has not been tested, and revisions of histologic classification in the 2015 classification 12 potentially allow further refinement of criteria within CHA. We therefore sought to assess the reproducibility of CHA and to identify the most useful histologic features.
Methods
To test consistency of opinion among a panel of pathologists on the question of primary versus metastatic lung adenocarcinoma in multiple tumor nodules, pathology members of the multiple nodules subgroup of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and invited participants from the International Association for the Study of Lung Cancer Pathology Committee, a group comprising a global representation of practicing pathologists with specialist interest in lung cancer, assessed whether two or more nodules in each case were SPLCs, IPM, or a combination of both by using an image-linked on-line survey. After review of a training cohort of five cases, 14 one representative slide from each nodule resected from a test cohort of 48 patients was scanned into an image database using an Aperio AT2 slide scanner (Leica Biosystems) with an Â40 objective. The cases comprised a sequential series of cases from 2013 and 2014 with multiple resected nodules identified within the diagnostic archive of Royal Brompton Hospital. Digitized images were linked to specific questions via a URL, and participants filled in their answers online until the survey was completed. A sample form is shown in Figure 1 . Participants were aware of the site of each nodule but not the nodal Figure 1 . A representative image from the sample survey form.
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Interobserver Variation in Lung Cancerstatus of the case, and no immunohistochemical or molecular data were provided. A Red Cap database with online survey capabilities was created for data entry and tracking at the University of Colorado. The database incorporated a registration (demographic) survey and a case-by-case passwordprotected review survey. Participants provided a histologic diagnosis for each nodule, with additional subtyping of adenocarcinomas according to the 2015 WHO classification of lung tumors 12 and scoring of a detailed set of histologic parameters. The criteria for CHA were based primarily on those of Girard et al., 2 with additional parameters proposed at meetings reviewing the initial training study. These included the presence or absence of features such as lepidic growth or similarities of morphologic features in comparing tumors side by side, such as cell size, mitotic rate, and nuclear pleomorphism ( Table 1) .
The study was approved within the Royal Brompton and Harefield National Health Service Foundation Trust as a service evaluation study in the context of assessing the reproducibility of pathologists in applying current staging and histologic criteria. To determine which histologic features weighed most heavily in arriving at a final determination of SPLC/IPM status, we studied the independent effects of each question posed in the survey. The results for each pathologist were summed across all tumor pairs for each question. We included data from all pathologists (N ¼ 17 with an effective sample size of n ¼ 16, as one scorer did not complete the survey for all 48 tumor pairs). We included only conclusions of SPLC or IPM and excluded instances in which the pathologist entered "inconclusive" (Table 3 ). Data were reduced to 2 Â 2 tables in which findings were categorized as similar versus dissimilar, none/inconsistent versus present in both or all, etc., and the conclusions were primary or metastasis. Differences in proportions in these 2 Â 2 tables were determined by using Fisher's exact tests. The number of pathologists with significant differences in findings by histologic feature (Fisher's exact test p < 0.05) was tabulated for each category (Table 4 ). The findings for each pathologic feature were also tested by using a binomial test to determine whether the number was different from 50-50 (i.e, from the result of a coin toss or, in other words, from chance alone). For example, 14 of 16 or 10 of 16 was tested against eight of 16. A p value less than 0.05 indicated that the number of pathologists with a significant difference is different from chance (half the pathologists found a difference and half did not).
Statistical Analysis
All analyses were performed with SAS software (version 9.4, SAS Institute, Cary, NC) and GraphPad Prism (version 7.01, GraphPad Software, La Jolla, CA). All statistical tests were two sided, with a p value less than 0.05 determining a statistically significant finding. 
Results
The overall results are summarized in a consensus diagram ( Fig. 2) with cases sorted horizontally according to the number of nodules evaluated in each case. Sixteen pathologists completed the survey (21 questions), evaluating 126 tumors from 48 patients and generating more than 42,000 data points. One pathologist partially completed the survey. Excluding uncertain diagnoses, there were four cases that were unanimously scored as SPLC and 10 as IPM. In a further eight cases, a large majority of pathologists (at least 12 of 16) classified multiple nodules as SPLCs. Of these, six showed different major histologic types and six showed multiple histologic subtypes of ADC, two with more than two nodules.
There was strong agreement between SPLC/IPM status among panelists and reference diagnosis, with overall agreement of 81% (k 0.596) ( Table 3 ). There was also good agreement as measured by the Cohen k statistic (0.64, p < 0.0001) between WHO histologic pattern and SPLC/IPM status, but the relationship between histologic pattern and SPLC or IPM status was not identical (McNemar test, p < 0.0001). Figures 3 to 6 show examples of cases for which there were varying levels of agreement among those polled, as indicated in the figure legends.
To analyze components of CHA, the summed data from the tumor pairs for each question for each pathologist were tested for differences in proportions using the Fisher's exact test (Table 4) . Those with a p value less than 0.05 were considered to have found a difference in histologic feature that contributed to an SPLC or IPM conclusion. In addition, the number of pathologists with significant differences was summed and tested against the hypothesis that this number is different from the result of a coin toss (Table 5 ). For example, acinus formation significantly correlated with SPLC/IPM status for 15 of 16 pathologists (94%). A binomial test was used to determine whether 15 of 16 Figure 2 . In this consensus map, determination for second primary lung cancer (SPLC)/intrapulmonary metastasis (IPM) status is shown for each tumor sorted horizontally by number of tumors and all slide readers. As indicated in the first row, 31 cases with two tumors and 17 cases with more than two tumors were assessed. In four cases the unanimous opinion was that all nodules were SPLC, and 10 cases were unanimously determined to be metastases. In all but six cases most panelists agreed with the submitting opinion. In one case, the majority opinion was that a diagnosis could not be reached. Ref, reference; Dx, diagnosis. was different from 8 of 16, where 8 of 16 represents the expected proportion that was not different from a the result of a coin toss. The p value for this test was 0.0005, indicating that the number of pathologists who found a difference in proportions is better than random chance. Table 6 shows the numbers of pathologists who found significant differences for each finding by conclusion regarding primary or metastasis. For example, looking at the finding of "similar" for gland/ acinus formation in the "difference by finding" columns, 14 out of 16 (88%) pathologists found that there was a difference in the distribution of conclusions of primary or metastatic; that is, they found that similar acinus formation was more likely to be associated with a conclusion of metastatic tumor. A binomial test was used to determine whether the number of pathologists was different from the result of a coin toss. A significant p value in cases in which the number of significant findings was small (e.g., three of 16 or zero of 17) was thought to be noninformative in choosing between primary or metastatic tumors, as most of the pathologists found no difference.
Discussion
Our study demonstrates that a panel of practicing pulmonary pathologists has good agreement in using CHA to distinguish SPLC from IPM. This supports the concept that morphology is a powerful tool in addressing this problem.
Multiple tumor nodules are an increasingly frequent finding in clinical practice and highlight the complex biology of lung cancer, especially adenocarcinoma of the lung. Although historically the default staging approach has been to view multiple tumor nodules in the lung as IPM and to stage them as T3 if present in the same lobe, T4 if present in a different ipsilateral lobe, and M1a if present in contralateral lobes, there is increasing recognition that multiple tumor nodules may represent SPLCs. SPLCs, especially those with ground glass appearances on imaging, have been associated with improved survival in comparison with IPMs, 9,10 and determination of SPLC/IPM status will be important in new staging algorithms and clinical trials. 15 However, it is noticeable that agreement was far from perfect, and consideration should be given to routine application of immunohistochemical and molecular testing to buttress histologic analysis. Studies of SPLCs report tumors either with EGFR mutations in only one tumor 16 or differing EGFR and KRAS mutations, 17 and comparative genomic analysis has shown a high level of concordance for recurrent alterations at first relapse in IPMs, 18 although the numbers in these studies are small. Others report that although comprehensive genotypic and morphologic assessment is feasible, it is not sufficient to establish their clonal relationship. 19 Indeed, further studies are needed to assess this challenging problem by using a multidisciplinary approach involving clinical (including survival data), radiologic, and immunohistochemical features and molecular data, as well as histologic features. Such an approach may be additionally informative in future staging studies and clinical trials when this issue is being addressed.
In addition, these data provide background information in creating machine algorithms for cellular diagnosis that are currently under development. 20, 21 The data suggest that concentration on nuclear features may be a way forward in the development of image analysis tests to identify tumor cells in mixed cell populations and support diagnosis of malignancy, dysplasia, second primary, or metastases.
This study not only examined agreement on the judgment exercised by a panel of experts in regard to metastatic status but also evaluated those microscopic features that go into making this determination. Similar acinar patterns, cell size, mitotic rate, nuclear pleomorphism, and nucleolar appearances were significantly associated with the final decision regarding SPLC/ IPM status, whereas alveolar clusters, cytoplasmic granules, lepidic growth, neutrophils, and vascular invasion were not. In parsing these data further, the statistical strength of these associations can be attributed to the direction of specific properties of a tumor. For example, similar acinus formation was associated with IPM but differing patterns of acinus formation did not associate with SPLC. When evaluated in this way, consistent cell size, similar mitotic rate, similar nuclear pleomorphism, and similar nucleolar abnormalities were all closely associated with metastasis, but the obverse was not true and inconsistency of these features was not associated with SPLC. Inconsistency of lepidic growth pattern, presence of alveolar clusters, necrosis pattern, mucin content, and neutrophil presence were associated with SPLC, whereas consistency of necrosis pattern and vascular invasion was associated with metastasis. In several categories, insufficient numbers of response were obtained to make valid comparisons and the survey responses to these questions were determined to be noninformative. There are several limitations to our study, including the lack of clinical follow-up, immunohistochemistry, and molecular testing results and our inability to determine the combined effects of the pathologic categories. It was not possible to do a meaningful multivariate analysis to study the combined effects of the different findings from different pathologic categories as the effective sample size was only 16 pathologists. There were also too many pathologic categories compared with the number of pathologists, which limits the power for a multivariate analysis. By studying the categories individually, we were not able to ascertain interactions between findings and conclusions by category. For example, even though we found that similar acinus formation was associated with a conclusion of metastasis, we could not state that similar acinus formation alone was sufficient for the pathologist to conclude that a second tumor was a metastasis of the first tumor. The pathologist undoubtedly takes a more general view of several pathologic findings to reach a conclusion regarding SPLC/ IPM status. Despite this limitation, this study still provides an interesting picture of the importance of several nuclear features taken together relative to the other categories.
We conclude that CHA shows good reproducibility between practicing lung pathologists. In addition to main tumor type and predominant patterns, nuclear pleomorphism, cell size, acinus formation, nucleolar size, and mitotic rate strongly correlated with pathologic staging status. Inconsistency between other features, such as lepidic growth pattern, also likely contribute to the reductionist evaluation that pathologists undertake when assessing multiple tumor nodules (Fig. 7) . How this correlates with molecular analysis is a subject for further study.
